Skip to main content
Equibles

Sara Bonstein

CFO

INSMED Inc (INSM)

Equibles does not estimate personal net worth.

Get an email with a short summary when INSMED Inc publishes a filing, an earnings call transcript or a press release.

Get INSM alerts

About Sara Bonstein

Sara Bonstein is recorded as CFO at INSMED Inc (INSM). The newest filing on record that lists Sara Bonstein as CFO at INSMED Inc (INSM) is dated April 1, 2026. The proxy statement of INSMED Inc reports total compensation of $4,617,429 for Sara Bonstein in fiscal 2025, including a base salary of $583,190. Disclosed compensation is on record for 8 fiscal years. Sara Bonstein has spoken on 25 earnings calls and 1 other investor event across 1 company, most recently for INSMED Inc on October 29, 2026. INSMED Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at INSMED Inc includes William H. Lewis (CEO and Board Member), William Lewis (CEO), Paolo Tombesi (CFO) and 7 others.

Sara Bonstein on recent calls

“I'm pleased to share our third quarter, 2026 financial results and updated guidance. Brent Supri produced $400.1 million in revenue in the third quarter, up 29% sequentially from an exceptionally strong second quarter.”
CFO, Q3 FY2026 Earnings conference call (announced in 8-K) ·
“I'm pleased to share our second quarter, 2026 financial results and updated guidance, and to provide some commentary to help with your modeling. Rensubri produced $309.2 million in revenue in the second quarter, up 49% sequentially from an already strong first quarter, in which we saw a sequential growth of 44%.”
CFO, INSMED Inc Q2 FY2026 Earnings Call ·
“And I really kind of hang my hat on how did we do that? And it was really all around operational excellence.”
CFO, 2026 RBC Capital Markets Global Healthcare Conference ·
“Based on the strength of our performance so far in 2026, I am pleased to reiterate our guidance for this year, which can be seen on this slide, including full year revenue and gross to net guidance for BRINSUPRI and ARIKAYCE.”
CFO, INSMED Inc Q1 FY2026 Earnings Call ·
“On the heels of Roger's commercial review of our two approved products, I am pleased to report that we are raising our 2025 full-year global ARIKAYCE net revenue guidance to $420 million to $430 million, up from a range of $405 million to $425 million previously.”
CFO, INSMED Inc Q3 FY2025 Earnings Call ·

Affiliation history

  • INSMED Inc (INSM)

    CFO

    Proxy statement

    Current

    Start not stated–present

    Last confirmed April 1, 2026

Company network

Leadership on record at INSMED Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 INSMED Inc (INSM) $583,190 $4,617,429
2024 INSMED Inc (INSM) $530,170 $4,012,005
2023 INSMED Inc (INSM) $511,010 $4,559,582
2022 INSMED Inc (INSM) $477,580 $3,433,248
2021 INSMED Inc (INSM) $460,320 $3,452,077
2020 INSMED Inc (INSM) $386,615 $2,721,791
2019 INSMED Inc (INSM) — —
2018 INSMED Inc (INSM) — —

Recent activity

Show 14 earlier activities